A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

NCT ID: NCT00130169

Last Updated: 2015-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-01-31
• Study Completion Date: 2009-08-31

Brief Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 administered on Days 1 and 15 of a 28-day cycle in subjects with solid malignancies that have progressed following effective therapy or for which no effective therapy exists.

Conditions

Cancer, Malignant Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

E7974

Intervention Type: DRUG

Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.

Interventions

E7974

Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients must have a pathologically diagnosed, histologically or cytologically confirmed solid malignancy that has progressed following effective therapy or for which no effective therapy exists (including surgery or radiation therapy).

2. Patients must be >= 18 years of age.

3. Patients must have an Eastern Cooperative Oncology Group (ECOG) status of 0, 1 or 2.

4. Patients must have a life expectancy of >= 3 months.

5. Patients must have adequate renal function as evidenced by serum creatinine <= 1.5 mg/dL or creatinine clearance >= 40 mL/minute (min)

6. Patients must have adequate bone marrow function as evidenced by absolute neutrophil count >= 1,200/µL, hemoglobin of >= 9 g/dL (may be transfused), and platelet count (not transfused) >= 100,000/µL.

7. Patients must have adequate liver function as evidenced by bilirubin <= 1.5 mg/dL and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 times the upper limits of normal (ULN), unless related to liver involvement by tumor, in which case <= 5.0 times ULN.

8. Patients must be willing and able to sign written informed consent and be able to comply with the study protocol for the duration of the study.

9. Patients must be willing and able to undergo blood draw and urine sampling for PK in Cycle 1.

10. Patients may have either measurable or non-measurable disease.

For Prostate Cancer patients only being enrolled at the MTD expansion phase:

1. Males with histologically proven adenocarcinoma of the prostate that has progressed (i.e. a minimum of three successive baseline values to document two consecutive rises in Prostate Specific Antigen (PSA) (with the last value 5 ng/mL) taken at least one week apart prior to study entry) despite castration or maintenance of castrate-level testosterone (defined as serum testosterone 50 ng/dL or 1.7 nmol/L), during non-hormonal chemotherapy.

2. Patients must have failed at least one previous chemotherapeutic regimen with tubulin binding agents such as docetaxel.

Exclusion Criteria

1. Patients who have received chemotherapy within three weeks of E7974 treatment start (6 weeks for a nitrosourea).

2. Patients who have not recovered from any chemotherapy-related or other therapy-related toxicity to <= Grade 1 at study entry (excluding Grade 2 alopecia).

3. Patients who have received radiotherapy <= 3 weeks prior to study enrollment, whose marrow exposure has exceeded 25% and who have not recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia).

4. Patients who have had major surgery without full recovery or major surgery within three weeks of E7974 treatment start.

5. Patients with primary brain tumors or metastasis at study entry must have controlled them for >= 1 month by previous treatment, including radiation therapy and corticosteroids.

6. Women who are pregnant or breastfeeding.

7. Women of childbearing potential with either a positive serum pregnancy test at screening or no pregnancy test.

8. Women of childbearing potential unless (1) surgically sterile, (2) physiologically postmenopausal for >= 12 months, or (3) using adequate measures (including barrier methods) of contraception.

9. Fertile men or their partners who are not willing to use contraception.

10. Patients who have a history of positive testing for Human Immunodeficiency Virus (HIV) and/or have active hepatitis B or active hepatitis C at study entry.

11. Patients with severe, uncontrolled intercurrent illness or infection.

12. Patients with medically uncontrolled cardiovascular illness defined as unstable angina, >= symptomatic Grade II New York Heart Association (NYHA) Classification congestive heart failure (CHF), or myocardial infarction within six months prior to study entry.

13. Patients who have received organ allografts requiring immunosuppressive therapy.

14. Patients who have received investigational drugs including immunotherapy, gene therapy, hormone therapy, biologic therapy, or chemotherapy within the three-week period prior to E7974 treatment start; patients must have recovered from any previous major therapy-related toxicities (Grade 3 or 4) to <= Grade 1 at study entry (excluding Grade 2 alopecia).

15. Patients with a current history of peripheral neuropathy > CTC Grade 1 (e.g., diabetic or chemotherapy-induced neuropathy).

16. Patients with a history of uncontrolled seizures.

17. Patients with marked baseline prolongation of QT/QTc interval (QTc interval >470) using the Fridericia method as the main method of QTc analysis.

18. Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study.

19. Patients with allergy or hypersensitivity to hemiasterlin based product or analogue.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eisai Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Naseem Zojwalla, M.D.

Role: STUDY_DIRECTOR

Eisai Inc.

Locations

Nevada Cancer Institute

Las Vegas, Nevada, United States

University Hospital Medical Center - SUNY at Stony Brook

Stony Brook, New York, United States

Countries

United States

Other Identifiers

E7974-A001-102

Identifier Type: -

Identifier Source: org_study_id